-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Downgrades Centessa Pharmaceuticals to Market Perform, Raises Price Target to $40

Benzinga·04/01/2026 20:28:30
Listen to the news
Leerink Partners analyst David Risinger downgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Outperform to Market Perform and raises the price target from $36 to $40.